Point72 Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Point72 Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-36,608	Closed	-$3.14M	–	1313
2020 Q4	$3.14M	Buy	+36,608	New	+$3.1M	0.02%	660
2020 Q1	–	Sell	-454,989	Closed	-$24.8M	–	1232
2019 Q4	$24.8M	Buy	+454,989	New	+$22.5M	0.13%	222
2018 Q4	–	Sell	-75,000	Closed	-$2.82M	–	1363
2018 Q3	$2.82M	Buy	+75,000	New	+$2.76M	0.01%	706

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management's BHVN Position: Q1 2021 in Review

Point72 Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 36,608 shares — an estimated $3.14M sold.

Point72 Asset Management first reported a position in BHVN in Q3 2018 and held it in 3 quarters. The position peaked at $24.8M in Q4 2019. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

Point72 Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
Point72 Asset Management sold 36,608 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $3.14M.
Point72 Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 3 quarters.
Point72 Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $24.8M in Q4 2019.
224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Point72 Asset Management's 13F filing for Q1 2021, filed 17 May 2021.